Stockscreener 앱 받기
77.55
0.23%
0.175
시장 영업 전:
77.90
0.35
+0.45%
전일 마감가:
$77.38
열려 있는:
$77.84
하루 거래량:
2.52M
Relative Volume:
1.35
시가총액:
$15.01B
수익:
$4.41B
순이익/손실:
$21.27M
주가수익비율:
242.34
EPS:
0.32
순현금흐름:
$288.81M
1주 성능:
+9.70%
1개월 성능:
+13.43%
6개월 성능:
+5.12%
1년 성능:
+14.40%
1일 변동 폭
$76.87
$78.77
1주일 범위
$69.69
$78.77
52주 변동 폭
$53.56
$83.95
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
77.55 | 14.98B | 4.41B | 21.27M | 288.81M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 업그레이드 | Stifel | Hold → Buy |
| 2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 개시 | UBS | Neutral |
| 2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-01 | 개시 | Wolfe Research | Outperform |
| 2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
| 2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 개시 | Deutsche Bank | Hold |
| 2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 개시 | Jefferies | Buy |
| 2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-25 | 개시 | Citigroup | Buy |
| 2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 개시 | Piper Sandler | Overweight |
| 2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-07-28 | 개시 | Wells Fargo | Equal Weight |
| 2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 개시 | Truist | Buy |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-06-16 | 개시 | The Benchmark Company | Hold |
| 2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 재개 | William Blair | Outperform |
| 2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 재개 | BofA/Merrill | Neutral |
| 2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
| 2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-10-03 | 개시 | Mizuho | Buy |
| 2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
| 2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 개시 | Credit Suisse | Neutral |
| 2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 개시 | Stifel | Hold |
| 2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - jammulinksnews.com
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo.co
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - Reuters
Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com
Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize
Celestica, Corning, And Incyte Impress With Upbeat Quarterly Results - Finimize
Incyte lifts annual sales forecast for blood cancer drug after solid quarter - whbl.com
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - Yahoo Finance
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq
Incyte Q2 Results Top Estimates - Nasdaq
Incyte Corp. Achieves Strong Financial Performance in Q2News and Statistics - IndexBox
Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates - Nasdaq
Incyte: Q2 Earnings Snapshot - NewsTimes
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada
Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus
Incyte Reports 2025 Second Quarter Financial Results - TradingView
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire
Incyte (INCY) Anticipates Q2 Earnings with Positive Expectations - GuruFocus
How volatile is Incyte Corporation stock compared to the marketRealize exceptional returns through smart trading - jammulinksnews.com
Does Incyte Corporation stock perform well during market downturnsNavigate market shifts with confidence - jammulinksnews.com
What makes Incyte Corporation stock attractive to long term investors5x Profit Potential - metal.it
Why Incyte Corporation stock attracts strong analyst attentionQuick Profit Idea Stream - beatles.ru
Earnings Preview: Incyte to Report Financial Results Pre-market on July 29 - 富途牛牛
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards? - MSN
Incyte to present initial data on cancer therapies at ESMO Congress - Investing.com
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 - Business Wire
What analysts say about Incyte Corporation stockFree Buy/Sell Signal Notifications - Autocar Professional
What drives Incyte Corporation stock priceHigh-impact stock picks - jammulinksnews.com
Incyte (INCY) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Incyte Corporation a good long term investmentTremendous return rates - jammulinksnews.com
Is BrightSpring Health Services, Inc. (BTSG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Incyte EVP Flannelly sells $83k in shares - Investing.com
Incyte EVP Flannelly sells $83k in shares By Investing.com - Investing.com UK
Sun Pharma launches Leqselvi in US; settles litigation with Incyte Corp - MSN
Incyte Announces Q2 2025 Financial Results Call and Webcast Details - MyChesCo
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
0.17%
자본화:
|
볼륨(24시간):